Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis

201829 citationsJournal Articlehybrid Open Access

Authors

William H. Isacoff · University of California, Los Angeles

Howard A. Reber · University of California, Los Angeles

Rudolph A. Bedford · University of California, Los Angeles

William Hoos · Pancreatic Cancer Action Network

Lola Rahib · Pancreatic Cancer Action Network

Alexander Upfill‐Brown · University of California, Los Angeles

Timothy R. Donahue

Abstract

This non-gemcitabine-based regimen resulted in higher response rates and better survival than what is commonly observed with therapy given at conventional dosing schedules. Low-dose continuous (metronomic therapy) cytotoxic chemotherapy combined with antiangiogenic therapy is safe and effective.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Cancer Treatment and Pharmacology Colorectal Cancer Treatments and Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Targeted Oncology

Volume 13, Issue 4, pp. 461-468

DOI: 10.1007/s11523-018-0572-3

Field-Weighted Citation Impact: 1.42